Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines
出版年份 2016 全文链接
标题
Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines
作者
关键词
-
出版物
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Volume 45, Issue 3, Pages 288-296
出版商
Wiley
发表日期
2016-09-20
DOI
10.1111/ceo.12838
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
- (2016) J. Van den Bossche et al. MEDICINAL RESEARCH REVIEWS
- BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments
- (2015) Rodrigo F.E. Bogado et al. ANTI-CANCER DRUGS
- Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters
- (2015) Lata Singh et al. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors
- (2015) Melanie Schwermer et al. Oncotarget
- A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
- (2014) C-C Lin et al. BRITISH JOURNAL OF CANCER
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Bora and Aurora-A continue to activate Plk1 in mitosis
- (2013) Wytse Bruinsma et al. JOURNAL OF CELL SCIENCE
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
- (2013) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells
- (2012) Peter S Harris et al. BMC CANCER
- Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications
- (2012) Francis L Munier et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Retinoblastoma
- (2012) Helen Dimaras et al. LANCET
- Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma
- (2012) Justina McEvoy et al. PLoS One
- Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
- (2011) D. Olmos et al. CLINICAL CANCER RESEARCH
- Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma
- (2010) S. Ackermann et al. CLINICAL CANCER RESEARCH
- Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells
- (2010) N N Kreis et al. ONCOGENE
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness
- (2009) F Cimmino et al. ONCOGENE
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
- (2009) P. Schoffski ONCOLOGIST
- The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint
- (2008) Florian Bassermann et al. CELL
- Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression
- (2008) Zheng Fu et al. NATURE CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now